A committee created by the French Agency for the Safety of Medicines and Health Products (ANSM) has drafted a list of rules concerning cannabis ahead of a two-year medical cannabis experiment.
The committee will be focused on a number of areas, including:
- Products available to patients during the trial.
- Relevant doctor and pharmacist cannabis training.
- A patient registry to evaluate experiment over 2 year period.
This study could potentially be a huge breakthrough for the European medical cannabis market. Up to now, Germany has had the only success with sales of medical cannabis but the committee’s findings could change all that.
Until June 2013, the use of medical cannabis was strictly prohibited. However, since then legislation has allowed cannabis-based medications with French or European marketing authorization.
The study will give overseas cannabis companies the chance to export their products to what may eventually be one of the biggest cannabis markets.
The ANSM approved committee will be composed of eighteen experts, health professionals and patient representatives. They are expected to work together for six months.